BiotechTube

Donepezil Hydrochloride (Aricept)

ApprovedWithdrawn
2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Severe Alzheimer's Disease

Conditions

Severe Alzheimer's Disease

Trial Timeline

Jan 1, 2008 → —

NCT ID
NCT00711204

About Donepezil Hydrochloride (Aricept)

Donepezil Hydrochloride (Aricept) is a approved stage product being developed by Eisai for Severe Alzheimer's Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00711204. Target conditions include Severe Alzheimer's Disease.

What happened to similar drugs?

20 of 20 similar drugs in Severe Alzheimer's Disease were approved

Approved (20) Terminated (5) Active (0)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅tacrolimusAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅CefiderocolShionogiApproved
✅Donepezil HClEisaiApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
✅drotrecogin alfa (activated)Eli LillyApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00675025Phase 2Terminated
NCT00711204ApprovedWithdrawn
NCT00165763ApprovedCompleted

Competing Products

20 competing products in Severe Alzheimer's Disease

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Drotrecogin alfa (activated)Eli LillyPhase 2
35
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
CS-3150Daiichi SankyoPhase 3
40
tacrolimusAstellas PharmaApproved
43
enzalutamideAstellas PharmaPhase 1
29
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
32
AlefaceptAstellas PharmaApproved
43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
CefiderocolShionogiApproved
50
eritoran tetrasodium + PlaceboEisaiPhase 3
40
Donepezil HClEisaiApproved
43
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827 + PlaceboKyowa KirinPhase 3
40